Lexeo Therapeutics, Inc. Financing Cash Flow
Lexeo Therapeutics, Inc. (LXEO) reported Financing Cash Flow of $26.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Lexeo Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $24.40M, a 66.56% decline year-over-year.
- Lexeo Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $2.45M, a 22190.91% increase year-over-year.
- Lexeo Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $143.77M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $52.00K.
- Lexeo Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $216.79M, a 144.20% increase from fiscal 2024.
- Lexeo Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $88.78M, a 14.47% decline from fiscal 2023.
- Lexeo Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $103.79M, a 54815.87% increase from fiscal 2022.
- Lexeo Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $189.00K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $26.85M 10-Q · filed 2026-08-12 | $170.62M derived: sum of 3 quarters · filed 2026-08-12 | $170.68M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.45M 10-Q · filed 2026-05-11 | $146.22M derived: sum of 2 quarters · filed 2026-05-11 | $146.28M derived: sum of 3 quarters · filed 2026-05-11 | $219.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $143.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $143.82M derived: sum of 2 quarters · filed 2026-03-30 | $216.78M derived: sum of 3 quarters · filed 2026-08-12 | $216.79M 10-K · filed 2026-03-30 |
| 2025-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $73.01M derived: sum of 2 quarters · filed 2026-08-12 | $73.02M 10-Q · filed 2025-11-05 | $72.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $72.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $72.97M 10-Q · filed 2026-08-12 | $72.87M derived: sum of 3 quarters · filed 2026-08-12 | $72.80M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $11.00K 10-Q · filed 2026-05-11 | -$86.00K derived: sum of 2 quarters · filed 2026-05-11 | -$158.00K derived: sum of 3 quarters · filed 2026-05-11 | $133.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$169.00K derived: sum of 2 quarters · filed 2026-03-30 | $122.00K derived: sum of 3 quarters · filed 2026-03-30 | $88.78M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $219.00K derived: sum of 2 quarters · filed 2025-11-05 | $88.87M 10-Q · filed 2025-11-05 | $188.94M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $291.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $88.94M 10-Q · filed 2025-08-14 | $189.02M derived: sum of 3 quarters · filed 2025-08-14 | $192.93M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $88.65M 10-Q · filed 2025-05-12 | $188.72M derived: sum of 2 quarters · filed 2025-05-12 | $192.64M derived: sum of 3 quarters · filed 2025-05-12 | $192.54M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $100.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $103.98M derived: sum of 2 quarters · filed 2025-03-24 | $103.89M derived: sum of 3 quarters · filed 2025-03-24 | $103.79M 10-K · filed 2025-03-24 |
| 2023-09-30 | $3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.82M derived: sum of 2 quarters · filed 2024-11-13 | $3.72M 10-Q · filed 2024-11-13 | $3.64M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$192.00K 10-Q · filed 2024-08-12 | -$273.00K derived: sum of 3 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$98.00K 10-Q · filed 2024-05-09 | -$179.00K derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $189.00K 10-K · filed 2024-03-11 | ||
| 2022-09-30 | $270.00K 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |